Common Contracts
3 similar Underwriting Agreement contracts by Intec Pharma Ltd., Poniard Pharmaceuticals, Inc., Viking Therapeutics, Inc.
INTEC PHARMA LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
Intec Pharma Ltd., a company organized and existing under the laws of the State of Israel, public company number ● (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom Maxim Group LLC and Roth Capital Partners, LLC are together acting as representatives (in such capacity, the “Representatives”), an aggregate of ● Ordinary Shares (the “Firm Shares”), no par value (the “Ordinary Shares”), of the Company. The Company has granted the Underwriters the option to purchase an aggregate of up to ● Ordinary Shares (the “Option Shares”) as may be necessary to cover over-allotments made in connection with the offering. The Firm Shares and Option Shares are collectively referred to as the “Shares.”
Shares VIKING THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 2nd, 2014 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
Viking Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained in this agreement (this “Agreement”), to sell to you and the other underwriters named on Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively referred to herein as the “Shares.”
UNDERWRITING AGREEMENTUnderwriting Agreement • April 25th, 2007 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
Poniard Pharmaceuticals, Inc., a Washington Corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 10,302,905 shares (the “Firm Shares”) of the Company’s common stock, $0.02 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,545,436 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
